Olivier Mir

Summary

Country: France

Publications

  1. ncbi request reprint The commonest primary sites for metastatic disease to the ovaries
    Olivier Mir
    J Surg Oncol 96:639-40. 2007
  2. doi request reprint Ectopic pregnancy in a breast cancer patient receiving trastuzumab
    Paul Berveiller
    Université Paris Descartes Faculté de Médecine, Department of Obstetrics, Hospital Notre Dame de Bon Secours, Paris, France
    Reprod Toxicol 25:286-8. 2008
  3. pmc Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
    Olivier Mir
    Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    PLoS ONE 7:e37563. 2012
  4. doi request reprint Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
    Olivier Mir
    Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors CERIA, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, 27, rue du Faubourg Saint Jacques, 75014, Paris, France
    Med Oncol 29:2793-9. 2012
  5. doi request reprint Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma
    Olivier Mir
    Sarcoma Unit, Cochin Teaching Hospital, Universite Paris Descartes, France
    Anticancer Drugs 23:745-8. 2012
  6. doi request reprint Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, France
    Anticancer Drugs 23:739-44. 2012
  7. doi request reprint Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, Universite Paris Descartes, Sorbonne Paris Cité, AP HP, Paris, France
    Support Care Cancer 20:2235-9. 2012
  8. doi request reprint Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Lung Cancer 77:104-9. 2012
  9. doi request reprint Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients
    Olivier Mir
    Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors, Paris, France
    Invest New Drugs 30:1756-60. 2012
  10. doi request reprint Vaccination coverage among medical residents in Paris, France
    O Mir
    SIHP, Syndicat des Internes des Hôpitaux de Paris, 17 Rue du Fer a Moulin, Paris, France
    Clin Microbiol Infect 18:E137-9. 2012

Collaborators

Detail Information

Publications60

  1. ncbi request reprint The commonest primary sites for metastatic disease to the ovaries
    Olivier Mir
    J Surg Oncol 96:639-40. 2007
  2. doi request reprint Ectopic pregnancy in a breast cancer patient receiving trastuzumab
    Paul Berveiller
    Université Paris Descartes Faculté de Médecine, Department of Obstetrics, Hospital Notre Dame de Bon Secours, Paris, France
    Reprod Toxicol 25:286-8. 2008
    ..Given the importance of HER-2 in embryo implantation and fetal development, its putative role in this abnormal embryo implantation should be discussed...
  3. pmc Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
    Olivier Mir
    Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    PLoS ONE 7:e37563. 2012
    ..Sorafenib induces frequent dose limiting toxicities (DLT) in patients with advanced hepatocellular carcinoma (HCC). Sarcopenia has been associated with poor performance status and shortened survival in cancer patients...
  4. doi request reprint Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
    Olivier Mir
    Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors CERIA, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, 27, rue du Faubourg Saint Jacques, 75014, Paris, France
    Med Oncol 29:2793-9. 2012
    ..8) vs. 3.8 months (95% CI: 2.5-3.9), p=0.017]. In our experience, gemcitabine-oxaliplatin was feasible and had detectable clinical activity in HCC patients pre-treated with sorafenib. Further studies are needed to confirm these findings...
  5. doi request reprint Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma
    Olivier Mir
    Sarcoma Unit, Cochin Teaching Hospital, Universite Paris Descartes, France
    Anticancer Drugs 23:745-8. 2012
    ....
  6. doi request reprint Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, France
    Anticancer Drugs 23:739-44. 2012
    ..7-5.2), P less than 0.01, respectively. In our experience, gemcitabine-oxaliplatin was feasible and induced effective palliation in PS2 patients with advanced BTC. Further studies are warranted to confirm these findings...
  7. doi request reprint Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, Universite Paris Descartes, Sorbonne Paris Cité, AP HP, Paris, France
    Support Care Cancer 20:2235-9. 2012
    ....
  8. doi request reprint Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer
    Olivier Mir
    Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Lung Cancer 77:104-9. 2012
    ..The combination of pemetrexed, oxaliplatin and bevacizumab appeared well tolerated and active as second- or third-line treatment in a previous phase II study. Its role as first-line therapy remains to define...
  9. doi request reprint Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients
    Olivier Mir
    Department of Medical Oncology, Centre for Research on Angiogenesis Inhibitors, Paris, France
    Invest New Drugs 30:1756-60. 2012
    ..We evaluated the impact of a shortened bevacizumab infusion (10 min) on toxicity in nonsmall cell lung cancer (NSCLC) patients...
  10. doi request reprint Vaccination coverage among medical residents in Paris, France
    O Mir
    SIHP, Syndicat des Internes des Hôpitaux de Paris, 17 Rue du Fer a Moulin, Paris, France
    Clin Microbiol Infect 18:E137-9. 2012
    ..Further immunization programmes should target residents, and not only senior healthcare workers, with a critical role for occupational medicine departments...
  11. doi request reprint Treatment of bevacizumab-induced hypertension by amlodipine
    Olivier Mir
    Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Paris Descartes University, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Invest New Drugs 30:702-7. 2012
    ..This study aimed to describe the efficacy and tolerability of amlodipine, a calcium channel blocker, in patients with metastatic malignancies treated with bevacizumab, a humanized monoclonal antibody to VEGF...
  12. doi request reprint Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience
    Olivier Mir
    Department of Medical Oncology, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Teaching Hospital Cochin, 27 rue du Faubourg Saint Jacques, Paris, France
    Anticancer Drugs 20:105-8. 2009
    ..This doublet allows combining a platinum derivative with a sustained dose intensity of vinorelbine in unfit patients...
  13. doi request reprint Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
    Olivier Mir
    Sarcoma Unit, Herault Ward, Department of Medicine, Institut Gustave Roussy, Université Paris 11, 39 rue Camille Desmoulins, Villejuif, France
    Eur J Cancer 47:515-9. 2011
    ..A sizeable population of elderly patients with STS is unfit for conventional doxorubicin- or ifosfamide-based chemotherapy. We assessed the feasibility of metronomic oral cyclophosphamide (CPM) in this population...
  14. doi request reprint Accidental blood exposures among medical residents in Paris, France
    O Mir
    SIHP, Syndicat des Internes des Hôpitaux de Paris, France
    Clin Microbiol Infect 17:464-6. 2011
    ..Medical residents behaved inappropriately in 33% of cases in this survey. Further educational programmes should include residents, and not only senior healthcare workers, in order to improve individual behaviours...
  15. doi request reprint Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy
    Olivier Mir
    Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud University, 39, rue Camille Desmoulins, 94800 Villejuif Cedex, France
    Cancer Chemother Pharmacol 69:357-67. 2012
    ..Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy...
  16. doi request reprint Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma
    Olivier Mir
    Department of Medical Oncology, Teaching Hospital Cochin, Universite Paris Descartes, Assistance Publique, Hopitaux de Paris, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Cancer Chemother Pharmacol 66:1059-63. 2010
    ..To evaluate the reliability and renal safety of an original schedule of high-dose methotrexate (HDMTX) administration with hyper-alkalinization, and without hyper-hydration...
  17. pmc An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity
    Olivier Mir
    Department of Medical Oncology, Teaching Hospital Cochin, AP HP, Universite Paris Descartes, 27 rue du Faubourg Saint Jacques, F75014 Paris, France
    Oncologist 16:1325-32. 2011
    ..This study aimed to describe the incidence of bevacizumab-induced hypertension and factors associated with its development, then to retrospectively assess its relation with activity...
  18. doi request reprint Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity
    O Mir
    Department of Medical Oncology, Teaching Hospital Cochin, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Paris, France
    Ann Oncol 20:736-40. 2009
    ....
  19. doi request reprint Use of platinum derivatives during pregnancy
    Olivier Mir
    Department of Medical Oncology, Assistance Publique Hopitaux de Paris, Faculty of Medicine, Cochin Teaching Hospital, Paris Descartes University, Paris, France
    Cancer 113:3069-74. 2008
    ....
  20. ncbi request reprint Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms
    Olivier Mir
    Department of Oncology, Assistance Publique Hopitaux de Paris, Hopital Cochin, University Paris 5, Faculty of Medicine, Paris, France
    Gynecol Oncol 106:622-5. 2007
    ..Non-bacterial thrombotic endocarditis is a severe complication of cancer, rarely reported in gynecologic tumors. However, it can be inaugural and lead to complex diagnostic pathways...
  21. ncbi request reprint Emerging therapeutic options for breast cancer chemotherapy during pregnancy
    O Mir
    Department of Medical Oncology, Université Paris Descartes Faculté de Médecine, Hopital Cochin, Assistance Publique Hopitaux de Paris, 27, rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Ann Oncol 19:607-13. 2008
    ..Anthracycline-based chemotherapy is feasible during the 2nd and 3rd trimesters of pregnancy, but few data are available on recent and highly active drugs taxanes, vinorelbine and anti-HER-2 agents in this setting...
  22. doi request reprint Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib
    Romain Coriat
    Center for Research on Angiogenesis Inhibitor, Universite Paris Descartes, AP HP, Teaching Hospital Cochin, Paris, France
    Invest New Drugs 29:1090-3. 2011
    ..Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents...
  23. doi request reprint Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma
    Charline Gomo
    Centre évaluation et de recours des inhibiteurs de l angiogénèse CERIA, GH Cochin Hôtel Dieu, 27 rue Faubourg Saint Jacques, Paris, 75014, France
    Invest New Drugs 29:1511-4. 2011
    ..The clinical relevance of pharmacokinetic interactions involving CYP3A4 inhibition in HCC patients receiving sorafenib is analyzed in this case report...
  24. pmc Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib
    Romain Coriat
    Center for Research on Angiogenesis Inhibitors CERIA, Hopital Cochin, AP HP, Paris, France
    PLoS ONE 6:e16978. 2011
    ..No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients...
  25. pmc Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis
    Pascaline Boudou-Rouquette
    Center for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Paris Descartes University, Sorbonne Paris Cité, 27 rue du Faubourg Saint Jacques, Paris, France
    Oncologist 17:1204-12. 2012
    ..Sorafenib displays major interpatient pharmacokinetic variability. It is unknown whether the pharmacokinetics of sorafenib influence its toxicity...
  26. doi request reprint Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients
    Romain Coriat
    Department of Medical Oncology, Teaching Hospital Cochin, AP HP, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, 75014, Paris, France
    Cancer Chemother Pharmacol 65:491-5. 2010
    ..With the development of 5-day infusion devices, we developed and evaluated a 5-day infusion regimen of ifosfamide in sarcoma patients in the outpatient setting...
  27. doi request reprint Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis
    Marion Dhooge
    Department of Gastroenterology, Cochin Teaching Hospital, AP HP, Paris, France
    Oncology 84:32-8. 2013
    ..We aimed to evaluate the feasibility of GEMOX in HCC patients with Child-Pugh B cirrhosis ineligible for sorafenib...
  28. doi request reprint A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia
    Marie Dior
    Department of Gastroenterology, Cochin Teaching Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Am J Med 125:828-30. 2012
    ..Bevacizumab, a monoclonal antibody to vascular endothelial growth factor-A, is approved for the treatment of various malignancies, and its hematological toxicities are considered infrequent...
  29. doi request reprint Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients
    Romain Coriat
    Center for Research on Angiogenesis Inhibitors CERIA, Universite Paris Descartes, AP HP, Cochin Teaching Hospital, Paris, France
    Invest New Drugs 30:376-81. 2012
    ..We conducted a retrospective study to evaluate the safety and the effectiveness of FOLFOX-4 in cirrhotic or liver transplanted patients with hepatocellular carcinoma ineligible for sorafenib...
  30. doi request reprint Cervical extravasation of bevacizumab
    Johann Dréanic
    Departments of Gastroenterology, Cochin Teaching Hospital, AP HP, Sorbonne Paris Cité, Paris Descartes University, Paris, France
    Anticancer Drugs 24:426-8. 2013
    ..Conservative management was proposed. The patient recovered within 3 weeks from all symptoms. Physicians should be aware that in cases of bevacizumab extravasation, a nonsurgical approach might be effective...
  31. pmc Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study
    Pascaline Boudou-Rouquette
    Centre d étude et de recours sur les inhibiteurs de l angiogénèse, Paris, France
    PLoS ONE 7:e42875. 2012
    ....
  32. pmc Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy
    Romain Coriat
    Cochin Teaching Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    J Oncol Pract 8:205-10. 2012
    ..This emerging issue may increase health care costs. We studied the cost effectiveness of a hospital-home monitoring program based on systematic iterative telephone calls after chemotherapy...
  33. doi request reprint Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
    Jennifer Arrondeau
    CERIA Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, F75014, Paris, France
    Invest New Drugs 30:2046-9. 2012
    ..Intra-patient variability in sorafenib pharmacokinetics has been poorly investigated to date. We hypothesized that sorafenib clearance could decrease over time, as seen with imatinib...
  34. doi request reprint Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model
    Paul Berveiller
    Department of Clinical Pharmacology and Clinical Research Unit, INSERM Cliniques P 0901, Cochin Teaching Hospital, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Am J Obstet Gynecol 207:514.e1-7. 2012
    ..The use of taxanes (paclitaxel and docetaxel) in pregnant cancer patients is increasing. We aimed to compare their transplacental transfer using the gold standard human placental perfusion model, to guide drug selection...
  35. doi request reprint Saturable absorption of sorafenib in patients with solid tumors: a population model
    Marilyne Hornecker
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, Hopital Cochin, 75014, Paris, France
    Invest New Drugs 30:1991-2000. 2012
    ..6 vs 91.5 mg/L.h for 400 mg q6h and 800 mg q12h, respectively). Thrice daily regimen may be most suitable in a context of dose-escalation (>800 mg/day) in non-responders to standard-dosing regimen...
  36. doi request reprint Reactivation of tuberculosis during temsirolimus therapy
    Romain Coriat
    Department of Medical Oncology, Cochin Teaching Hospital, Paris Descartes University, AP HP, 27, rue du Faubourg Saint Jacques, F75014, Paris, France
    Invest New Drugs 29:1494-6. 2011
    ..After introduction of rifampicin-based treatment, the patient experienced tumour progression, leaving questionable the potential pharmacokinetic interaction between rifampicin and temsirolimus, a substrate for CYP3A4...
  37. ncbi request reprint [Oral drugs inhibiting the VEGF pathway]
    Stanislas Ropert
    Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris
    Bull Cancer 94:S180-90. 2007
    ..Moreover, none of the agents are specifically anti-angiogenic and the respective parts of the "off target" effects are difficult to evaluate. Simple and reliable surrogate markers of toxicity and efficacy are still lacking...
  38. doi request reprint VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption
    Stanislas Ropert
    Centre for Research on Angiogenesis Inhibitors CERIA, Department of Medical Oncology, AP HP, Cochin Teaching Hospital, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, F75014, Paris, France
    Invest New Drugs 29:1497-9. 2011
    ....
  39. doi request reprint Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients
    Jean Philippe Durand
    Department of Medical Oncology, University Hospital Cochin, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Support Care Cancer 20:857-64. 2012
    ..Oncologists often overestimate survival of advanced cancer patients. This study aimed to validate a score for survival prediction in terminally ill cancer patients...
  40. doi request reprint A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma
    Lionel Faivre
    Laboratoire de Pharmacologie Toxicologie, Service de Pharmacie, GH Cochin Hôtel Dieu Broca, AP HP, Paris, France
    J Chromatogr B Analyt Technol Biomed Life Sci 879:2345-50. 2011
    ..This simple, sensitive, accurate and cost-effective method can be used in routine clinical practice to monitor gefitinib or erlotinib concentrations in plasma from NSCLC patients...
  41. ncbi request reprint Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities
    Olivier Mir
    Unité d Oncologie Médicale, Service de Medecine Interne, Hopital Cochin, GHU Ouest, Assistance Publique Hopitaux de Paris, Paris, France
    Anticancer Drugs 16:1017-21. 2005
    ....
  42. doi request reprint Sarcoidosis lung nodules in colorectal cancer follow-up: sarcoidosis or not?
    Marie Lequoy
    Gastroenterology and Endoscopy Unit, Hopital Cochin, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Am J Med 126:642-5. 2013
    ..Its pathologic hallmark is the presence of noncaseating granulomas. Sarcoidosis is a chronic inflammatory condition that may increase the risk of cancer, yet at the same time, cancer can be associated with a sarcoid-like reaction...
  43. doi request reprint Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies
    Johann Dréanic
    Gastro Enterology and Digestive Oncology Unit, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Med Oncol 30:656. 2013
    ..2, 14 and 12.1 months, respectively (p = 0.0093). The results of the present study confirm that the GPS is still a simple and effective prognostic factor in the era of cetuximab therapy in mCRC patients...
  44. doi request reprint Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
    Camille Tlemsani
    CERIA Centre for Research on Angiogenesis Inhibitors, Department of Medical Oncology, Cochin Teaching Hospital, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, France
    Target Oncol 6:253-8. 2011
    ..The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents...
  45. doi request reprint Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Universite Paris Sud, Villejuif, France
    Ann Surg Oncol 21:269-76. 2014
    ..This study was designed to evaluate the impact of multimodal management on a series of epithelioid sarcoma (ES) patients treated with curative intent...
  46. doi request reprint Prognostic scoring systems for spinal metastases in the era of anti-VEGF therapies
    Thomas M Gregory
    Department of Orthopaedic Surgery, European Hospital Georges Pompidou, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Spine (Phila Pa 1976) 38:965-6. 2013
    ..Spine Update on prognostic scoring systems for spinal metastases in the era of anti-vascular endothelial growth factor (VEGF) therapies...
  47. ncbi request reprint Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer
    Valerie Martinez
    Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Teaching Hospital Cochin, University Paris 5, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Anticancer Drugs 18:233-5. 2007
    ..This clinical observation invites us to reconsider the number of administrations to be recommended for mitoxantrone-sensitive metastatic prostate cancer patients...
  48. doi request reprint A dramatic fetal outcome following transplacental transfer of dasatinib
    Paul Berveiller
    PremUp Foundation, INSERM U, Pharmaceutical and Biological Sciences Faculty, Teaching Hospital Cochin Saint Vincent de Paul, AP HP, Universite Paris Descartes, France
    Anticancer Drugs 23:754-7. 2012
    ..Hence, this case highlights the imputability of dasatinib in this adverse outcome, and clearly questions its safety during pregnancy...
  49. doi request reprint Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases
    Edouard Lecarpentier
    Department of Digestive and General Surgery, Teaching Hospital Cochin, AP HP, Paris, France
    Invest New Drugs 29:1500-3. 2011
    ..Vessels were morphologically normal with tumoral cells' morphology and architecture identical to the primary breast carcinoma. Chemotherapy was not reintroduced after surgery and the patient died on the 57th postoperative day...
  50. doi request reprint [Chemotherapy in unfit bladder cancer patients]
    F Goldwasser
    Groupe Hospitalier Cochin, Unité de cancérologie, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, France
    Bull Cancer 97:35-41. 2010
    ..The physician must also have a honest dialogue to inform, advise, listen to the patients priorities. Medical oncologists have to have in mind this situation and to adapt their clinic and their vocabulary to this emerging reality...
  51. ncbi request reprint Esophageal involvement as an initial manifestation of Churg-Strauss syndrome
    Olivier Mir
    Service de Medecine Interne, centre de référence maladies rares, Hopital Cochin, AP HP, Universite Paris Descartes, Paris
    Presse Med 36:57-60. 2007
    ..Churg-Strauss syndrome (CSS) is a systemic disease characterized by asthma, blood and tissue eosinophilia, and necrotizing vasculitis with extravascular eosinophilic granulomas...
  52. doi request reprint Fertility-sparing approach in a teenager with uterine tumor diagnosed as a sarcoma on imaging
    Paul Berveiller
    Department of Gynecology and Obstetrics, Teaching Hospital Saint Antoine, Assistance Publique, Hopitaux de Paris, Pierre et Marie Curie University, Paris, France
    Gynecol Obstet Invest 69:157-9. 2010
    ..Uterine tumors are extremely rare in teenage patients. Although magnetic resonance imaging (MRI) can help distinguish between leiomyoma and sarcoma, it may also seriously mislead the diagnosis...
  53. ncbi request reprint Raltegravir-induced DRESS syndrome
    Pierre Loulergue
    CIC de vaccinologie Cochin Pasteur, Hopital Cochin, 27, rue du Faubourg Saint Jacques, F75014 Paris, France
    Scand J Infect Dis 44:802-3. 2012
    ..The presented case is the first description of a proven raltegravir-induced DRESS syndrome...
  54. doi request reprint Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model
    Paul Berveiller
    Clinical Research Unit, Institut National de la Sante et de la Recherche Medicale, Cochin Teaching Hospital, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, France
    Am J Obstet Gynecol 206:92.e1-6. 2012
    ....
  55. doi request reprint Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma
    Thomas Gregory
    Department of Orthopaedic Surgery, Faculte de Medecine, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Med Oncol 27:446-8. 2010
    ..This is an unexpected adverse event, given the mechanism of action of the drug. The pathophysiology of this event remains unexplained, although we describe some hypotheses...
  56. doi request reprint Genetic polymorphisms of matrix metalloproteinase 12 and 13 genes are implicated in endometriosis progression
    Bruno Borghese
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Service de Gynécologie Obstétrique II, CHU Cochin Saint Vincent de Paul, Paris, France
    Hum Reprod 23:1207-13. 2008
    ..Matrix metalloproteinases (MMPs) may contribute to endometriosis. We tested whether eight functional polymorphisms of these genes could modify the risk of endometriosis...
  57. ncbi request reprint Trastuzumab--mechanism of action and use
    Olivier Mir
    N Engl J Med 357:1664-5; author reply 1665-6. 2007
  58. ncbi request reprint Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
    Olivier Mir
    J Natl Cancer Inst 99:85-6. 2007
  59. doi request reprint [Taxane-induced skin toxicity and TNF-alpha]
    Olivier Mir
    Presse Med 37:252-3. 2008
  60. doi request reprint Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma
    Pierre Loulergue
    AIDS 22:1237-9. 2008